Pharmaceutical agents provide diagnostic and therapeutic utility that are central to patient
care. However, all agents also carry adverse drug effect profiles. While most of these are …

Immune checkpoint inhibitors have dramatically improved cancer therapy for many patients.
These humanized monoclonal antibodies against various immune checkpoints (receptors …

Nephrotoxicity from cancer therapies is common and increasingly encountered in clinical
practice, such that the subfield of “onco-nephrology” has emerged. Conventional …

Background Despite increasing recognition of the importance of immune checkpoint
inhibitor–associated AKI, data on this complication of immunotherapy are sparse. Methods …

Immune checkpoint inhibitors that target the programmed death 1 (PD-1) signaling pathway
have recently been approved for use in advanced pretreated non–small cell lung cancer …

Cardiovascular disease is a major cause of graft loss and the leading cause of death in
renal transplant recipients. Although there are robust data on the frequency of risk factors …

Morbidity and mortality associated with viral infections increase with age, although the
underlying mechanisms are unclear. Here, we investigated whether aging alters …

The development of immune checkpoint inhibitors (ICIs) has driven a revolutionary change
in cancer treatment. Although traditional chemotherapeutic agents remain the first-line …

The NLRP3 inflammasome is activated in the lung during influenza viral infection; however,
the impact of aging on inflammasome function during influenza infection has not been …

Background In patients receiving immune checkpoint inhibitor (ICI) therapy, acute kidney
injury (AKI) is common, and can occur either from kidney injury unrelated to ICI use or from …